<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920346</url>
  </required_header>
  <id_info>
    <org_study_id>13-1879</org_study_id>
    <nct_id>NCT02920346</nct_id>
  </id_info>
  <brief_title>Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor</brief_title>
  <official_title>Heart Sounds at Home: Prospective Maternal Surveillance of SSA Positive Pregnancies Using a Hand-Held Fetal Heart Rate Monitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stollery Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins All Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research study &quot;Heart Sounds at Home&quot; is for pregnant SSA or SSA/SSB
      (Sjögren syndrome B) antibody positive mothers to use a Doppler fetal heart rate monitor to
      detect abnormal heart rates and rhythms in their babies before they are born.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll mothers during week 16-19 of gestation and will ask the mothers to use
      a hand-held Doppler monitor to listen to the baby's heart rate and rhythm twice daily from
      about week 16 to week 26 of the pregnancy. Pregnant mothers will be asked to keep a log of
      the heart rates and will undergo a fetal echocardiogram every 2 weeks during their study
      participation. In addition to these procedures, the study team will collect the mother's
      medical and obstetrical histories. Should irregular heart rhythms be detected at home, the
      mother will contact the investigator to be evaluated. After the baby is delivered, the study
      team will collect information about the baby's birth and heart rhythm evaluation
      (electrocardiogram).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Fetal AV (atrio-ventricular) heart block</measure>
    <time_frame>Date of randomization until the date of first documented progression, assessed up to 41 weeks.</time_frame>
    <description>Development of fetal AV heart block will be determined by the principal investigator's analysis of the fetal echocardiogram.</description>
  </primary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <condition>Neonatal Systemic Lupus Erythematosus</condition>
  <condition>Fetal Heart Block Complete</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all pregnant women with positive SSA or SSA and SSB
        antibodies between the gestational ages of 16-19 weeks with no signs of antibody-mediated
        fetal cardiac disease on pre-enrollment fetal echocardiogram. Subjects who are more than 19
        weeks gestation will not be included. Subjects who have a fetus with an estimated fetal
        weight below the 10th percentile will also not be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with positive SSA or SSA and SSB antibodies

          -  Gestational age (GA) between 16 and 19 weeks

          -  No signs of antibody-mediated fetal cardiac disease on pre-enrollment echo

        Exclusion Criteria:

          -  Subjects who are more than 19 weeks gestation

          -  Subjects who have a fetus with an estimated fetal weight below the 10th percentile
             will also not be included
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina F Cuneo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina F Cuneo, MD</last_name>
    <phone>(720)777-6820</phone>
    <email>bettina.cuneo@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Halley J Isberg, BA</last_name>
    <phone>(720) 777-9514</phone>
    <email>halley.isberg@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halley J Isberg, BA</last_name>
      <phone>720-777-9514</phone>
      <email>Halley.Isberg@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan A Brocato, BA</last_name>
      <phone>720-777-8864</phone>
      <email>megan.brocato@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bettina F Cuneo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa W. Howley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.heartsoundsathome.com</url>
    <description>study website</description>
  </link>
  <reference>
    <citation>Cuneo BF, Strasburger JF, Niksch A, Ovadia M, Wakai RT. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med. 2009 Mar;22(3):233-8. doi: 10.1080/14767050802488220.</citation>
    <PMID>19330707</PMID>
  </reference>
  <reference>
    <citation>Cuneo BF, Lee M, Roberson D, Niksch A, Ovadia M, Parilla BV, Benson DW. A management strategy for fetal immune-mediated atrioventricular block. J Matern Fetal Neonatal Med. 2010 Dec;23(12):1400-5. doi: 10.3109/14767051003728237. Epub 2010 Apr 12.</citation>
    <PMID>20384469</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal Systemic lupus erythematosus</keyword>
  <keyword>Sjogren's syndrome</keyword>
  <keyword>Fetal Atrioventricular Block</keyword>
  <keyword>Fetal Heart Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Heart Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

